What are the key financial results for Amgen in Q3 1998?

The provided text is a directory listing of the SEC filing and does not contain the detailed financial statements or the Management's Discussion and Analysis (MD&A) section. Therefore, specific financial results such as revenue, net income, or earnings per share are not available from this excerpt. Investors would need to access the full 10-Q filing to obtain this information.

What were Amgen's main products and their performance during this quarter?

This filing excerpt does not detail specific product performance. Amgen's primary products at that time were typically Epogen (for anemia) and Neupogen (for neutropenia). To understand their sales performance and contribution to Amgen's results in Q3 1998, investors would need to review the full 10-Q report, specifically the MD&A section.

Were there any significant business developments or strategic updates reported by Amgen in this filing?

The provided text is only a directory listing and does not include the narrative sections of the 10-Q that would typically discuss significant business developments, pipeline updates, clinical trial results, or strategic initiatives. These details would be found within the complete filing document.

AMGN 10-Q Quarterly Report Q3 FY1998 — Revenue, Net Income, EPS

Summary

Amgen Inc. (AMGN) reported its third-quarter results for the period ending September 29, 1998. While the provided filing excerpt is primarily a directory listing and does not contain detailed financial statements or management's discussion and analysis, it indicates the filing of a Form 10-Q. Investors would typically look for information on revenue growth, profitability, product sales performance (especially key drugs like Epogen and Neupogen), pipeline developments, and any significant business events or acquisitions. Without the full report, specific financial metrics and strategic insights are unavailable, but the filing signifies Amgen's ongoing compliance and reporting obligations during a period of growth in the biotechnology sector.

Key Highlights

1Amgen Inc. (AMGN) filed its quarterly report (10-Q) for the period ending September 29, 1998, indicating ongoing financial reporting.
2The filing was made on November 15, 1998, adhering to regulatory timelines.
3This report covers a critical growth period for biotechnology companies, suggesting potential updates on product sales and pipeline progress.
4Investors would typically seek detailed financial performance, including revenue and profit figures, within the full 10-Q document.
5The filing implies that Amgen continued to operate and generate business activity throughout the third quarter of 1998.
6Understanding Amgen's performance in this period is key to assessing its trajectory in the late 1990s biotechnology landscape.

AMGEN INC Quarterly Report for Q3 Ended Sep 30, 1998

Summary

Key Highlights

Frequently Asked Questions